Following positive Phase IIb trial results, RH5.1/Matrix-M has the potential to be the first blood-stage malaria vaccine brought to market.
Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.
Alumis has revealed encouraging results from a Phase I clinical trial of tyrosine kinase 2 (TYK2), A-005, in healthy subjects.
Sorriso Pharmaceuticals announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.
Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.
The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from low-middle income countries.